Technology/ Title

Development of Anti-Mesothelin x CD3 BsAb for Mesothelin+ Cancer Therapy

Technology Type

Biotechnology

Device/Diagnostics

Pharmaceutical

Others:_____________-

Contact Person

Name: Tony Chung

Title: Project Manager

Telephone(work): +886-02-7700-3800 ext. 5235

Mobile:

Email: tony.chung@dcb.org.tw

Link

http://

 

 

Technology Description

 

Summary of Invention:

Asymmetric IgG-like bispecific antibody (BsAb) is the trend of next generation antibody drug development. However, the mispairing issue between light chains and heavy chains is the bottleneck of this technology. DCB has developed an asymmetric anti-mesothelin x CD3 BsAb and overcome this technological hurdle. The BsAb targets the mesothelin-overexpressing cancer cells such as pancreatic cancers, ovarian cancers, and mesotheliomas. Subsequently, it recruits and activates the T cell for cancer cell killing. The T cell activation is highly dependent on the presence of the cancer cell which elevates the safety profile of this anti-cancer drug. Its efficacy has been demonstrated and is better than its parental monoclonal antibody and fragment BsAb in the pancreatic cancer xenograft animal model. The BsAb possesses low immunogenicity property, and the production yield of its CHO-S stable clone is comparable to its parental mAb.

 

Advantages when compared to the existing technologies:

  1. Correct light chain and heavy chain pairing.
  2. Longer half-life.
  3. Target cancer cell-dependent T cell activation.
  4. Better anti-cancer efficacy compared to the short half-life fragment BsAb and its parental monoclonal antibody.
  5. High production yield comparable to its parental mAb.
  6. Low Immunogenicity in rodent.

Intellectual Property

TW, US, PCT patents applied

Key Publications

 

Business Opportunity

Cancer Therapy

Mesothelioma, pancreatic cancer, and ovarian cancer

 

 

 

 

▌技術簡介(現況)

非對稱性IgG-like雙特異性抗體已成為次世代抗體藥物開發主流,然而該項技術有抗體輕鏈與重鏈正確配對的瓶頸,生技中心所開發之非對稱性抗Mesothelin x CD3雙特異性抗體已成功克服此障礙,並利用抗體的一端標靶Mesothelin高表現的癌細胞,及anti-CD3的抗體端誘導T細胞至癌細胞周圍,以活化T細胞並進行癌細胞毒殺。此雙特異性抗體具有需標靶細胞存在下才能活化T細胞的特性,大大提升其用藥的安全性,且在胰臟癌動物試驗中已發現其療效較單株抗體藥物及Fragment雙特異性抗體為佳。

 

▌技術規格

人源化非對稱性IgG雙特異性抗體(asymmetric-BsAb)開發平台/ anti-Mesothelin/anti-CD3雙特異性抗體。

 

▌技術特色

針對癌細胞進行新世代標靶治療,利用雙特異性抗體標靶癌細胞抗原Mesothelin,並以anti-CD3抗體端誘導活化T細胞以進行癌細胞毒殺,其療效較傳統單株抗體及Fragment雙特異性抗體為佳。

 

▌應用範圍

Mesothelin高表現的Mesothelioma、胰臟癌、及卵巢癌之治療,或其他。

 

▌接受技術者具備基礎建議(設備)

一般分子生物學實驗設施、抗體表現與純化系統。

 

▌接受技術者具備基礎建議(專業)

抗體臨床前開發技能。

 

▌技術分類

抗體藥物開發。

 

▌專利狀態

產品已申請專利國家: 美國

技術平台已申請專利國家:美國、PCT、中華民國


聯絡人:鍾牧樺

TEL(02)7700-3800 #5235

E-mailtony.chung@dcb.org.tw

最後更新日期:2019.03.27